Niven Narain

Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor of the Interrogative Biology® platform that has unraveled actionable disease insight leading to both de novo and repurposed development of a deep pipeline of products in oncology, metabolic, rare, and CNS diseases, namely BPM 31510 currently in Phase 2 trials for cancer covered by over 650 issued and pending US and international patents.

Dr. Narain is a member of the NASA/Gene Lab Steering Committee, Advisor to US Department of Defense leadership on breast and prostate cancer and forged strategic partners with industry, academia, and US and UK governments. He serves on the Advisory Board of Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Healthy Aging Initiative Commission at No. 10 for the UK Prime Minister. He is an industry thought leader in precision medicine, drug development, and AI/ML serving as a frequent speaker at Economist, Bloomberg, Financial Times, Wired, and Aspen Ideas and many international meetings on medicine and technology.